A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer

被引:2
作者
Kida, Kumiko [1 ,2 ]
Yamada, Akimitsu [1 ]
Shimada, Kazuhiro [3 ,4 ]
Narui, Kazutaka [5 ]
Sugae, Sadatoshi [1 ,6 ]
Shimizu, Daisuke [7 ]
Doi, Takako [8 ]
Oba, Mari [9 ]
Endo, Itaru [1 ]
Ishikawa, Takashi [10 ]
机构
[1] Yokohama City Univ, Dept Gastroenterol Surg & Surg Oncol, Grad Sch Med, 3-9 Fukuura,Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan
[2] St Lukes Int Hosp, Dept Breast Surg Oncol, Tokyo, Japan
[3] Yokohama Municipal Citizens Hosp, Dept Breast Surg, Yokohama, Kanagawa, Japan
[4] Saiseikai Yokohamashi Nanbu Hosp, Dept Surg, Yokohama, Kanagawa, Japan
[5] Yokohama City Univ, Dept Breast & Thyroid Surg, Med Ctr, Yokohama, Kanagawa, Japan
[6] Fujisawa City Hosp, Dept Breast Surg, Fujisawa, Kanagawa, Japan
[7] Yokohama Minato Red Cross Hosp, Dept Breast Surg, Yokohama, Kanagawa, Japan
[8] Shonan Mem Hosp, Dept Breast Surg, Kamakura, Kanagawa, Japan
[9] Toho Univ, Dept Med Stat, Tokyo, Japan
[10] Tokyo Med Univ, Dept Breast Surg & Oncol, Tokyo, Japan
关键词
Chemotherapy induced peripheral neuropathy; Breast cancer; paclitaxel; Nab-paclitaxel; ALBUMIN-BOUND PACLITAXEL; RANDOMIZED PHASE-II; CHEMOTHERAPY; VEHICLE; NEUROTOXICITY; MANAGEMENT; INSTITUTE; TRIALS; TAXOL;
D O I
10.1007/s12282-024-01551-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundCharacteristics of taxane-induced peripheral neuropathy (PN) could be different between paclitaxel and nab-paclitaxel. The purpose of this prospective observational multicenter cohort study was to compare tri-weekly nab-paclitaxel to weekly standard paclitaxel regarding the severity, onset and recovery of sensory and motor PN in patients with breast cancer.MethodsPatients with histologically confirmed breast cancer who were scheduled to receive standard weekly paclitaxel (80 mg/m2) or tri-weekly nab-paclitaxel (260 mg/m2) at institutions in our multicenter group were eligible for this study. Sensory and motor PN were evaluated every 3 weeks until PN improved for up to one year using patient-reported outcome.ResultsBetween February 2011 and April 2013, 115 patients were enrolled, including 57 and 58 in the paclitaxel and nab-paclitaxel groups, respectively. The incidence of moderate or severe sensory PN was not significantly different between the two groups (p = 0.40). The incidence of moderate or higher motor PN was more frequent in the nab-paclitaxel group than in the paclitaxel group (p = 0.048). The median period for demonstrating PN were shorter in the nab-paclitaxel group than in the paclitaxel group (sensory, p = 0.003; motor, p = 0.001). The recovery of motor PN was slower in the nab-paclitaxel group than in the paclitaxel group (p = 0.035), while the recovery period of sensory PN was not statistically different.ConclusionNab-paclitaxel induced sensory PN sooner than paclitaxel, and no difference was observed in the severity and recovery duration between the two agents. Motor PN was more severe, started sooner, and improved over a longer period in the nab-paclitaxel-treated patients than in the paclitaxel-treated patients.
引用
收藏
页码:409 / 416
页数:8
相关论文
共 50 条
  • [41] nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial
    George Dranitsaris
    Robert Coleman
    William Gradishar
    Breast Cancer Research and Treatment, 2010, 119 : 717 - 724
  • [42] Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study
    Khalefa, Hadeer G.
    Shawki, May A.
    Aboelhassan, Rasha
    El Wakeel, Lamia M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 117 - 125
  • [43] Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
    Taira, Naruto
    Kashiwabara, Kosuke
    Tsurutani, Junji
    Kitada, Masahiro
    Takahashi, Masato
    Kato, Hiroaki
    Kikawa, Yuichiro
    Sakata, Eiko
    Naito, Yoichi
    Hasegawa, Yoshie
    Saito, Tsuyoshi
    Iwasa, Tsutomu
    Takashima, Tsutomu
    Aihara, Tomohiko
    Mukai, Hirofumi
    Hara, Fumikata
    BREAST CANCER, 2022, 29 (01) : 131 - 143
  • [44] Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
    Palumbo, Raffaella
    Sottotetti, Federico
    Trifiro, Giuseppe
    Piazza, Elena
    Ferzi, Antonella
    Gambaro, Anna
    Spinapolice, Elena Giulia
    Pozzi, Emma
    Tagliaferri, Barbara
    Teragni, Cristina
    Bernardo, Antonio
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2189 - 2199
  • [45] Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial
    Kanbayashi, Yuko
    Sakaguchi, Koichi
    Ishikawa, Takeshi
    Tabuchi, Yusuke
    Takagi, Ryo
    Yokota, Isao
    Katoh, Norito
    Takayama, Koichi
    Taguchi, Tetsuya
    MEDICAL ONCOLOGY, 2022, 39 (10)
  • [46] Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer
    Masashi Ando
    Kan Yonemori
    Noriyuki Katsumata
    Chikako Shimizu
    Taizo Hirata
    Harukaze Yamamoto
    Kenji Hashimoto
    Mayu Yunokawa
    Kenji Tamura
    Yasuhiro Fujiwara
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 457 - 465
  • [47] Predictors of the development of nab-paclitaxel-induced peripheral neuropathy in breast cancer patients: post hoc analysis of a prospective, phase II, self-controlled clinical trial
    Yuko Kanbayashi
    Koichi Sakaguchi
    Takeshi Ishikawa
    Yusuke Tabuchi
    Ryo Takagi
    Isao Yokota
    Norito Katoh
    Koichi Takayama
    Tetsuya Taguchi
    Medical Oncology, 39
  • [48] A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer
    Werner, Theresa L.
    Ray, Abhijit
    Lamb, John G.
    VanBrocklin, Matthew
    Hueftle, Kristin
    Cohen, Adam L.
    Beck, Anna C.
    Buys, Saundra S.
    Dyess, Donna L.
    Butler, Thomas W.
    Dumlao, Theresa L.
    Neumayer, Leigh
    Khong, Hung T.
    CLINICAL BREAST CANCER, 2017, 17 (07) : 503 - 509
  • [49] Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial
    Funasaka, Chikako
    Hanai, Akiko
    Zenda, Sadamoto
    Mori, Keita
    Fukui, Makoto
    Hirano, Nami
    Shinohara, Rie
    Fuse, Nozomu
    Wakabayashi, Masashi
    Itagaki, Mai
    Tomioka, Yutaka
    Nishina, Michihiko
    Arai, Yasuaki
    Kogawa, Takahiro
    Ozaki, Yukinori
    Nishimura, Meiko
    Kobayashi, Takayuki
    Hara, Fumikata
    Takano, Toshimi
    Mukohara, Toru
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer
    Lavasani, Sayeh M.
    Somlo, George
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Daniel
    Yeon, Christina
    Yuan, Yuan
    Waisman, James R.
    Mortimer, Joanne
    CANCER, 2023, 129 (05) : 740 - 749